A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Expansion Study of the Oral DNA Polymerase Theta Inhibitor (POLQi) GSK4524101 and the PARP Inhibitor (PARPi) Niraparib in Adult Participants With Solid Tumors
Latest Information Update: 11 Jun 2025
At a glance
- Drugs IDE 705 (Primary) ; Niraparib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors GSK
Most Recent Events
- 04 Jun 2025 Planned End Date changed from 9 Nov 2029 to 29 Jun 2027.
- 04 Jun 2025 Planned primary completion date changed from 30 Dec 2027 to 29 Jun 2027.
- 04 Jun 2024 Trial design presented at the 60th Annual Meeting of the American Society of Clinical Oncology.